3859 |
Current Status of Balloon-Expandable TAVR in Korea |
Jung-Min Ahn |
Apr. 27. 19 |
3858 |
Results and Update from the Vessix RE-INFORCE Program |
Martin Bert Leon |
Apr. 27. 19 |
3857 |
Global Update : Low-Risk TAVR |
Vinayak Bapat |
Apr. 27. 19 |
3856 |
Results and Update from the SPYRAL Hypertension Program(OFF-MED and ON-MED Trials) |
David E. Kandzari |
Apr. 27. 19 |
3855 |
RADIANCE HTN SOLO Off Trial: ReCor Medical Paradise Technology and Results |
Byeong-Keuk Kim |
Apr. 27. 19 |
3854 |
Invited Case Presentation & Focus Review: A LAD CTO of Retrograde Approach Via Septal Channel; Channel Selection and Negotiation |
Satoru Otsuji |
Apr. 27. 19 |
3853 |
The Future of the Bioresorbable Scaffolds: Is Still Clinical Unmet Need? |
Michael Haude |
Apr. 27. 19 |
3852 |
Drug-Coated Balloons: Contemporary Best Indication and Future Perspective |
Do-Yoon Kang |
Apr. 27. 19 |
3851 |
Invited Case Presentation & Focus Review: Treatment of Severe Calcified Lesion: OCT-guided Step-by Step Approach |
Takashi Akasaka |
Apr. 27. 19 |
3850 |
Lessons from ABSORB: How to Improve the Scaffold Outcomes with Imaging |
Yoshinobu Onuma |
Apr. 27. 19 |